This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): tobramycin inhaled solution
Description: Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death.
Historical revenues includes revenues for TOBI Podhaler.
TOBI was developed by PathoGenesis, which was then acquired by Chiron, which was then acquired by Novartis.
On an undisclosed date, DRI Capital purchased royalties relating to the sales of TOBI for pseudomonas aeruginosa infection in cystic fibrosis. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.
Partners: DRI Capital Inc.
Pink Sheet PathoGenesis Tobi
Pink Sheet In Brief: Pathogenesis TOBI
Additional information available to subscribers only: